Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Amortization of Deferred Charges (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Amortization of Deferred Charges for 16 consecutive years, with $7100.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges fell 20.55% to $7100.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23185.0 through Dec 2025, down 18.11% year-over-year, with the annual reading at $23185.0 for FY2025, 18.11% down from the prior year.
  • Amortization of Deferred Charges hit $7100.0 in Q4 2025 for Cumberland Pharmaceuticals, up from $5362.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $13833.0 in Q1 2021 to a low of $110.0 in Q4 2021.
  • Historically, Amortization of Deferred Charges has averaged $5615.6 across 5 years, with a median of $4570.0 in 2023.
  • Biggest five-year swings in Amortization of Deferred Charges: crashed 99.04% in 2021 and later skyrocketed 3199.09% in 2022.
  • Year by year, Amortization of Deferred Charges stood at $110.0 in 2021, then surged by 3199.09% to $3629.0 in 2022, then grew by 4.99% to $3810.0 in 2023, then skyrocketed by 134.54% to $8936.0 in 2024, then decreased by 20.55% to $7100.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for CPIX at $7100.0 in Q4 2025, $5362.0 in Q3 2025, and $5361.0 in Q2 2025.